Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Natera Inc (NTRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Natera Announces Pricing of Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of...

NTRA : 18.86 (-0.11%)
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives

NTRA : 18.86 (-0.11%)
CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients

CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United...

NTRA : 18.86 (-0.11%)
CDNA : 25.95 (-1.93%)
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA,...

NTRA : 18.86 (-0.11%)
Natera Inc Has Returned 38.1% Since SmarTrend Recommendation (NTRA)

SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on February 11th, 2019 at $14.87. In approximately 2 months, Natera Inc has returned 38.10% as of today's recent price of $20.54.

NTRA : 18.86 (-0.11%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Natera Inc (NTRA , ATRA , VCYT , ALKS , ALNY )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 22.92 (-1.88%)
NTRA : 18.86 (-0.11%)
ATRA : 33.41 (+0.54%)
Medicare Issues Draft Local Coverage Determination for Natera's New Prospera(TM) Kidney Transplant Rejection Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived...

NTRA : 18.86 (-0.11%)
Analysis: Positioning to Benefit within JD, Five9, Ambarella, Natera, Methanex, and Virtusa -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of JD.com, Inc. (NASDAQ:JD), Five9,...

NTRA : 18.86 (-0.11%)
AMBA : 50.44 (-1.62%)
MEOH : 54.40 (-5.21%)
VRTU : 53.63 (+0.41%)
JD : 29.23 (-1.45%)
FIVN : 51.62 (+0.78%)
CareDx Files Patent Infringement Lawsuit Against Natera

CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant...

NTRA : 18.86 (-0.11%)
CDNA : 25.95 (-1.93%)
Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number...

NTRA : 18.86 (-0.11%)
Uptrend Call Working As Natera Inc Stock Rises 37.8% (NTRA)

SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on February 11th, 2019 at $14.87. In approximately 1 month, Natera Inc has returned 37.79% as of today's recent price of $20.49.

NTRA : 18.86 (-0.11%)
Relatively Good Performance Detected in Shares of Cytokinetics Inc in the Biotechnology Industry (CYTK , AKBA , NTRA , UTHR , MGNX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

NTRA : 18.86 (-0.11%)
CYTK : 9.24 (-0.75%)
AKBA : 6.46 (+0.62%)
Natera Inc Has Returned 25.7% Since SmarTrend Recommendation (NTRA)

SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on February 11th, 2019 at $14.87. In approximately 1 month, Natera Inc has returned 25.69% as of today's recent price of $18.69.

NTRA : 18.86 (-0.11%)
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of -4.08% and 6.58%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

NTRA : 18.86 (-0.11%)
Natera: 4Q Earnings Snapshot

SAN CARLOS, Calif. (AP) _ Natera Inc. (NTRA) on Tuesday reported a loss of $31.8 million in its fourth quarter.

NTRA : 18.86 (-0.11%)
Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and year ended December 31,...

NTRA : 18.86 (-0.11%)
Natera, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Natera, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at 4:30 PM Eastern...

NTRA : 18.86 (-0.11%)
Amag Pharmaceuti has the Best Relative Performance in the Biotechnology Industry (AMAG , NVTA , NTRA , EXAS , BLUE )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NVTA : 23.17 (-1.40%)
NTRA : 18.86 (-0.11%)
AMAG : 11.82 (+0.08%)
Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq(TM) Technology Platform

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA clinical testing laboratory in China and one of the world's...

NTRA : 18.86 (-0.11%)
Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2018, after the market close on March 12, 2019. Natera...

NTRA : 18.86 (-0.11%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
AAON -0.48
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar